Nuvectis Pharma announced a collaboration with Mayo Clinic to evaluate NXP800 in an Investigator-sponsored clinical trial in cholangiocarcinoma. Mitesh Borad, M.D., an oncologist at Mayo Clinic Comprehensive Cancer Center in Arizona, will serve as the principal investigator for the trial.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on NVCT:
